Roche leads a fragmented companion diagnostics market as digital PCR gains ground

By AI, Created 4:20 AM UTC, May 21, 2026, /AGP/ – The companion diagnostics market remains highly fragmented, with F Hoffmann-La Roche Ltd. leading global sales in 2024 and the top 10 players holding just 8% of revenue. The latest market report points to digital PCR, AI-driven analytics and tighter drug-diagnostic alignment as the main forces shaping competition through 2035.

Why it matters: - Companion diagnostics help match patients to targeted therapies, especially in oncology and other precision medicine settings. - The market’s fragmentation leaves room for niche players, but also raises the bar on validation, regulation and clinical reliability. - Growth in biomarker testing, next-generation sequencing and PCR-based assays is pushing more investment into drug-linked diagnostics.

What happened: - The Business Research Company published its Companion Diagnostics Global Market Report 2026, covering market size, trends and forecasts through 2035. - F Hoffmann-La Roche Ltd. led global sales in 2024 with a 1% market share. - The top 10 companies held 8% of total market revenue in 2024. - Major companies in the market include Thermo Fisher Scientific, Qiagen, Illumina, Agilent, Abbott, Danaher, Guardant Health, Foundation Medicine and Siemens Healthcare.

The details: - Roche’s diagnostics division offers biomarker-based testing, molecular diagnostic assays, next-generation sequencing platforms and PCR-based systems for personalized medicine and targeted therapy selection. - The market is described as fragmented, with moderate barriers from clinical validation, assay development and regulatory approval requirements. - Competitive strength is tied to pharmaceutical partnerships, global distribution networks and continuous innovation in genomic sequencing and companion diagnostic assays. - Major raw material suppliers include Roche, Qiagen, Illumina, Thermo Fisher Scientific, Agilent, Bio-Rad, Danaher, PerkinElmer, Abbott and Sysmex. - Major wholesalers and distributors include McKesson, Cardinal Health, AmerisourceBergen, Henry Schein, Medline, Owens and Minor, Fisher Scientific International and VWR International. - Major end users include Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Massachusetts General Hospital, Stanford Health Care, Quest Diagnostics, Labcorp, NHS England Specialized Services and MD Anderson Cancer Center.

Between the lines: - Digital polymerase chain reaction systems are emerging as a key competitive edge because they improve biomarker quantification and patient matching. - The report’s emphasis on regulatory-aligned drug-diagnostic co-development suggests tighter integration between pharma and diagnostics firms. - AI-driven analytics and modern diagnostic infrastructure point to a market where software and data capabilities matter as much as lab hardware.

What’s next: - QIAGEN launched the QIAcuityDx digital PCR system in September 2024 for clinical oncology testing and companion diagnostic applications. - The system’s integrated workflow, dual operating modes and audit-ready software are designed to support laboratory efficiency and regulatory compliance. - The report says companies are likely to lean more on strategic collaborations, product innovation and regional expansion as demand for personalized medicine tools grows. - Request a free sample of the report - Access the full companion diagnostics report

The bottom line: - Roche leads a crowded market, but the next phase of competition will likely hinge on digital PCR, regulatory readiness and closer links to drug development.